Antares recently announced
that the FDA has agreed to review its application to market Anturol Gel as a treatment for overactive bladders, and expects to make a decision by early December. Approval of this application could send the shares up significantly.
Catalyst Pharmaceutical Partners, Inc. shares are trading for about $1.29. Back in 2007, First Albany had a $10 price target, while Stifel Nicolaus and Rodman and Renshaw both had $9 price targets with buy ratings. The buy ratings and $9 to $10 price targets were just before the financial crisis, and it seems like everyone has forgotten about this little biotech that clearly still has potential and has made significant progress over the past four years. One analyst still has a $9 price target, which you can see here
. CPRX has a very low burn rate compared to most biotechs; management has been conservative and made substantial purchases of this stock. The 52-week high is $1.54 and with volume picking up and the shares only about 30 cents away from that level, it looks like these shares could be ready to make new highs soon. The chart for this stock looks good as well, with the 50-day moving above the 200-day moving average, the chart shows a new golden cross formation, which often indicates the start of a new upward trend.
Catalyst has some big players invested in its stock. Federated Investors owns nearly 12% of this company and FMR, LLC (Fidelity) owns about 6%. Late last year, Catalyst began a $10 million clinical trial, the majority of which (about $7.2 million) is being paid by the government. The trial
is for CPP-109, "Vigabatrin," to treat cocaine addiction. The company also has CP-115, which it says
"has the potential to address a broad range of diseases affecting the central nervous system beyond addiction, such as adult epilepsy and infantile spasms." What intrigues me most about this is the following portion:
In 2010, Reckitt Benckiser's Suboxone(NYSE:R) and Subutex(R) became the first addiction drugs to achieve "blockbuster" status with combined U.S. sales of over $1 billion. Recognition of this milestone, along with the looming "patent cliff" faced by the world's largest pharmaceutical companies, has increased the number of companies interested in discussions about partnering opportunities for CPP-109 and CPP-115. While no definitive partnering agreements have been entered into to date, Catalyst's goal is to make significant progress on this front before the end of 2011.
An agreement to partner with a major pharmaceutical company would potentially send this stock soaring from current levels. CPP-109 has been granted fast track status by the FDA for the treatment of cocaine addiction, which indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. With a market cap of only about $24 million and the potential to bring a blockbuster drug to market, it would not be surprising to see a major company takeover CPRX or announce a major partnership agreement, which is one of the company goals for 2011.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY
) is trading around $10.47. ALNY is a biotechnology company based in Massachusetts. These shares have traded in a range between $8.79 to $17.59 in the last 52 weeks. The 50-day moving average is $9.77 and the 200-day moving average is $11.12. ALNY is estimated to lose about $1.22 per share in 2011 and post a loss of about $1.61 per share for 2012. In the product development pipeline
, Alnylam has candidates for Huntington's disease, liver cancer, RSV infections, anemia and more.
According to the latest data on shortsqueeze.com
, there are about 3.6 million shares short. Based on average volume of just about 182,000 shares traded per day, it would take about 20 days worth of volume to match the number of shares short.
Acorda Therapeutics is trading around $32. Acorda is a biotechnology company based in New York. These shares have traded in a range between $20.43 to $38.24 in the last 52 weeks. The 50-day moving average is $25.92 and the 200-day moving average is $26.90. ACOR is estimated to earn about 64 cents per share in 2011 and $1.21 in 2012.
Acorda has seen a surge in revenues from sales of its multiple sclerosis drug called Ampyra. You can read more about its latest quarter here
. An analyst at Cowen Healthcare Royalty Partners recently said
he thinks Acorda is a likely takeover target.
Biosante Pharmaceuticals, Inc. is trading around $3. Biosante is a biotechnology company based in Illinois. These shares have traded in a 52-week range between $1.29 to $2.60. The 50-day moving average is $2.26 and the 200-day moving average is $1.81. Earnings estimates for BPAX are for a loss of 49 cents per share for 2011 and loss of 13 cents for 2012.
BPAX has a licensing agreement with Teva Pharmaceuticals (NYSE:TEVA
) for Bio-T-Gel, which treats low testosterone levels. The NDA is pending with the FDA for this product and Teva is responsible for all regulatory and marketing. BPAX also has the right to receive up to $140 million in sales-based milestone payments from Azur for Elestrin (which targets estrogen) if it reaches certain predefined sales per calendar year. You can read more about this and other products in the pipeline here.
Insiders were buying
BPAX shares at the begininng of this year. It's easy to see why one of Biosante's existing partners or another major pharmaceutical company might buy this company outright. Biosante has a strong balance sheet with about $51 million in cash; see this and other financial details here
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX
) is trading around $5.42. Keryx is a biotechnology company based in New York. These shares have traded in a 52-week range between $3.03 to $5.92. The 50-day moving average is $5.03 and the 200-day moving average is $4.63. Earnings estimates for KERX are for a loss of 35 cents per share for 2011 and loss of 41 cents for 2012. In the product development pipeline
, Keryx has a number of interesting candidates.
A number of analysts
have recently put buy and market outperform rating on KERX shares. This company has two candidates -- Perifosine for multiple myeloma and colorectal cancer, and Zerenex
, which targets hyperphosphatemia in patients with end-stage renal disease -- both of which are currently in phase 3 trials.
Inhibitex, Inc. is trading around $4.59. Inhibitex is a biotechnology company based in Georgia. These shares have traded in a 52-week range between $1.31 to $5.23. The 50-day moving average is $3.88 and the 200-day moving average is $2.66. Earnings estimates for INHX are for a loss of 41 cents per share for 2011 and loss of 44 cents for 2012. In the product development pipeline
, Inhibitex has a number of interesting candidates.
Inhibitex's pipeline targets viral and bacterial infections, including herpes zoster (shingles), chronic hepatitis C, and S. aureus
infections. Inhibitex has a license and collaboration agreement with Pfizer (NYSE:PFE
) for the development of vaccines against staphylococcus.